3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Melanoma
8
Multiple Myeloma
6
Hematologic Neoplasms
6
Lymphoma
5
Neoplasm Metastasis
4
Thyroid Neoplasms
2
Glioma
2
Cholangiocarcinoma
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Bile Duct Neoplasms
2
Uveal Melanoma
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Cancer, Papillary
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neurofibromatosis 1
1
Lung Neoplasms
1
Leukemia, Myelomonocytic, Juvenile
1
Leukemia, Myeloid, Acute
1
Klatskin Tumor
1
Hemangioendothelioma, Epithelioid
1
Glioblastoma
1
Interventions
dehydroftorafur
2
Leucovorin
2
Fluorouracil
2
trametinib
1
binimetinib
1
Specimen Handling
1
Sorafenib
1
Oxaliplatin
1
Magnetic Resonance Spectroscopy
1
Erlotinib Hydrochloride
1
Capecitabine
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
NIH
×
Klatskin Tumor
×
trametinib
×
Clear all
NCT02042443
2017-09-12
S1310
National Cancer Institute (NCI)
Phase 2
Completed
53 enrolled
13 charts